Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog,

Slides:

Advertisements

Similar presentations

Atorvastatin Calcium Atorvastatin Calcium is an inhibitor of HMG-CoA reductase used as a cholesterol-lowering medication that blocks the production of.

Advertisements

Volume 82, Issue 12, Pages (December 2012)

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Management of IgA nephropathy: Evidence-based recommendations

Long-term evolution of cardiomyopathy in dialysis patients

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Beta blockers in the management of chronic kidney disease

Viper venom for diabetic nephropathy

Bettina Haslinger-Löffler Kidney International

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Volume 68, Issue 2, Pages (August 2005)

Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks Sripal Bangalore, MD, MHA, Gbenga Ogedegbe,

Francesco Locatelli, Lucia Del Vecchio, Simeone Andrulli, Sara Colzani

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

John P. Middleton, Patrick H. Pun Kidney International

Volume 82, Issue 12, Pages (December 2012)

Smoking and cardiovascular outcomes in dialysis patients: The United States Renal Data System Wave 2 Study1,2 Robert N. Foley, Charles A. Herzog, Allan.

Volume 81, Issue 7, Pages (April 2012)

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real? S. Andrulli, S. Di Filippo, F. Locatelli

Volume 80, Issue 9, Pages (November 2011)

Jeffrey C. Fink, Glenn M. Chertow Kidney International

Volume 94, Issue 3, Pages (September 2018)

Comorbidity and confounding in end-stage renal disease

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

Volume 74, Issue 3, Pages (August 2008)

Volume 74, Issue 5, Pages (September 2008)

Volume 72, Issue 12, Pages (December 2007)

Volume 77, Issue 2, Pages (January 2010)

The epidemiology of chronic kidney disease

Achieving blood pressure targets during dialysis improves control but increases intradialytic hypotension A. Davenport, C. Cox, R. Thuraisingham Kidney.

Acute myocardial infarction in patients with end-stage renal disease

Body size and outcomes on peritoneal dialysis in the United States

Blood pressure targets in hemodialysis patients

Volume 73, Issue 12, Pages (June 2008)

Volume 61, Issue 1, Pages (January 2002)

Günter Weiss, Florian Kronenberg Kidney International

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

The future of renoprotection: Frustration and promises

Presentation of the 2003 Jean Hamburger Award to Robert W. Schrier

Alternate-day dialysis may be needed for hemodialysis patients

Nephrology Crossword: Peritoneal Dialysis

Cardiovascular disease in pediatric chronic dialysis patients

Volume 84, Issue 5, Pages (November 2013)

Long-term evolution of cardiomyopathy in dialysis patients

Cardiovascular risk assessment in kidney transplantation

Volume 81, Issue 7, Pages (April 2012)

Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study1 Robert N. Foley, Charles A. Herzog, Allan J.

Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants C.A. Solid,

Carmine Zoccali, Francesca Mallamaci Kidney International

Volume 73, Issue 5, Pages (March 2008)

Current status of maintenance hemodialysis in Beijing, China

Organ transplantation goes to the movies

Does equal care give equal outcomes?

Volume 72, Issue 2, Pages (July 2007)

Long-term outcome of dialysis patients in the United States with coronary revascularization procedures Charles A. Herzog, M.D., Jennie Z. Ma, Allan J.

Volume 68, Issue 1, Pages (July 2005)

Charles A. Herzog Kidney International

Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley

Volume 86, Issue 2, Pages (August 2014)

Volume 70, Issue 5, Pages (September 2006)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Unadjusted odds ratio of death at 6 mo for medications (β blockers [BBL], angiotensin-converting enzyme inhibitors [ACEI]/angiotensin receptor blockers.

E.F. Vonesh, J.J. Snyder, R.N. Foley, A.J. Collins

Optimization of pre-ESRD care: The key to improved dialysis outcomes

Letter from W. Lornoy; I. Becaus; J.M. Billiouw and L. Sierens

Presentation transcript:

Cardiac medications and their association with cardiovascular events in incident dialysis patients: Cause or effect? Areef Ishani, Charles A. Herzog, Allan J. Collins, Robert N. Foley Kidney International Volume 65, Issue 3, Pages 1017-1025 (March 2004) DOI: 10.1111/j.1523-1755.2004.00473.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Association between baseline use of any calcium channel blocker (CCB) and various outcomes. Kidney International 2004 65, 1017-1025DOI: (10.1111/j.1523-1755.2004.00473.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Association between baseline use of any angiotensin-converting enzyme inhibitor (ACEI) and various outcomes. Kidney International 2004 65, 1017-1025DOI: (10.1111/j.1523-1755.2004.00473.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Association between baseline use of any HMG-CoA reductase inhibitor (statin) and various outcomes. Kidney International 2004 65, 1017-1025DOI: (10.1111/j.1523-1755.2004.00473.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Association between baseline use of any beta-blocker and various outcomes. Kidney International 2004 65, 1017-1025DOI: (10.1111/j.1523-1755.2004.00473.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Association between baseline use of any anti-platelet agent and various outcomes. Kidney International 2004 65, 1017-1025DOI: (10.1111/j.1523-1755.2004.00473.x) Copyright © 2004 International Society of Nephrology Terms and Conditions